CYTOGENETIC CHARACTERIZATION OF CHRONIC MYELOID LEUKEMIA AND ITS PROGNOSTIC IMPACT UPON TREATMENT WITH TYROSINE KINASE INHIBITORS

被引：0

作者：

Canamero, Giro Eloi ^{[1
]}

Garcia, Olga ^{[1
]}

Boque, Concepcion ^{[2
]}

Sitges, Marta ^{[3
]}

Vallansot, Rolando Omar ^{[4
]}

Cisneros, Adela ^{[1
]}

Cortes, Montserrat ^{[5
]}

Gener, Georgina ^{[6
]}

Vela, Dolors ^{[7
]}

Font, Llorenc ^{[8
]}

Pineda, Alberto ^{[9
]}

Xandri, Marisol ^{[1
]}

Santafe, Encarnacion ^{[1
]}

Espasa, Andrea ^{[1
]}

Comes, Martina ^{[1
]}

Xicoy, Blanca ^{[1
]}

Zamora, Lurdes ^{[1
]}

Granada, Isabel ^{[1
]}

Navarro, Jose Tomas ^{[1
]}

Grau, Javier ^{[1
]}

机构：

[1] Univ Autonoma Barcelona, Hosp Germans Trias & Pujol, Inst Catala Oncol, Inst Recerca Leucemia Josep Carreras, Barcelona, Spain

[2] ICO Hosp Duran & Reynals, Lhospitalet De Llobregat, Spain

[3] ICO Hosp Univ Josep Trueta, Girona, Spain

[4] Hosp Univ Joan XXIII, Tarragona, Spain

[5] Hosp Granollers, Granollers, Spain

[6] Hosp Mataro, Mataro, Spain

[7] Hosp Mollet del Valles, Mollet, Spain

[8] Hosp Verge de la Cinta, Tortosa, Spain

[9] Hosp Esperit St, Santa Coloma, Spain

来源：

HAEMATOLOGICA | 2020年 / 105卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

PO-057

引用

页码：169 / 170

页数：2

共 50 条

[21] Molecular monitoring in chronic myeloid leukemia - Response to tyrosine kinase inhibitors and prognostic implications
Jabbour, Elias
Cortes, Jorge E.
Kantarjian, Hagop M.
CANCER, 2008, 112 (10) : 2112 - 2118
[22] Placental transfer of tyrosine kinase inhibitors used for chronic myeloid leukemia treatment
Chelysheva, Ekaterina
Turkina, Anna
Polushkina, Evgenia
Shmakov, Roman
Zeifman, Alexey
Aleshin, Sergey
Shokhin, Igor
Guranda, Dorel
Oksenjuk, Oksana
Mordanov, Sergey
Kazakbaeva, Khamida
Chilov, Ghermes
LEUKEMIA & LYMPHOMA, 2018, 59 (03) : 733 - 738
[23] Adverse events associated with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia
Breccia, Massimo
Colafigli, Gioia
Molica, Matteo
Alimena, Giuliana
EXPERT OPINION ON DRUG SAFETY, 2016, 15 (04) : 525 - 533
[24] Management of Chronic Myeloid Leukemia Patients Resistant to Tyrosine Kinase Inhibitors Treatment
Wieczorek, Agnieszka
Uharek, Lutz
BIOMARKER INSIGHTS, 2015, 10 : 49 - 54
[25] Phase II trials of tyrosine kinase inhibitors in the treatment of chronic myeloid leukemia
Ghanem, Hady
Kantarjian, Hagop
Cortes, Jorge
Quintas-Cardama, Alfonso
Jabbour, Elias
EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (08): : 607 - 623
[26] Impact of Comorbidities on Survival of Chronic Myeloid Leukemia Patients Treated with Tyrosine Kinase Inhibitors
Engelbrecht, Fernanda F.
Miranda, Eliana C.
Delamain, Marcia Torresan
Duarte, Gislaine Borba
Souza, Carmino Antonio
De Paula, Erich V.
Pagnano, Katia B.
BLOOD, 2019, 134
[27] Mutations of resistance to tyrosine kinase inhibitors in chronic myeloid leukemia
Kihel, I.
Nachi, M.
Bekadja, M. A.
CLINICA CHIMICA ACTA, 2022, 530 : S334 - S335
[28] Unplanned discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia
Tsutsumi, Yutaka
Ito, Shinichi
Ohigashi, Hiroyuki
Shiratori, Souichi
Teshima, Takanori
MOLECULAR AND CLINICAL ONCOLOGY, 2016, 4 (01) : 89 - 92
[29] Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
Haznedaroglu, Ibrahim C.
TURKISH JOURNAL OF HEMATOLOGY, 2013, 30 (03) : 247 - 255
[30] Chronic myeloid leukemia, tyrosine kinase inhibitors and cardiovascular system
Malkan, U. Y.
Haznedaroglu, I. C.
EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2023, 27 (12) : 5493 - 5506

← 1 2 3 4 5 →